University of Utah - Huntsman Cancer Center
Welcome,         Profile    Billing    Logout  
 9 Trials 
11 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tran, Phuoc
SALV-ENZA, NCT02203695: Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy

Active, not recruiting
2
96
US
Enzalutamide, XTANDI, SRT, Salvage Radiation Therapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Astellas Pharma Inc, Medivation, Inc.
Adenocarcinoma of the Prostate
12/22
12/24
KNIGHTS, NCT06212583: High-Risk Metachronous Oligometastatic Prostate Cancer Trial

Recruiting
2
88
US
niraparib/abiraterone acetate, Stereotactic ablative radiation therapy (SABR), Androgen deprivation therapy (ADT)
University of Maryland, Baltimore, Janssen Scientific Affairs, LLC
Prostate Cancer, Oligometastatic Disease
12/28
12/29
RAVENS, NCT04037358: RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers

Active, not recruiting
2
64
US
Radium-223, stereotactic ablative radiotherapy (SABR)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Defense Congressionally Directed Medical Research Program, Bayer
Prostate Cancer
12/26
12/28
NCI-2020-04699, NCT04489719: Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

Recruiting
N/A
48
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Questionnaire Administration, Radium Ra 223 Dichloride, Alpharadin, BAY 88-8223, BAY88-8223, Radium 223 Dichloride, RADIUM RA-223 DICHLORIDE, Radium-223 Dichloride, Xofigo
University of Washington, Bayer
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
08/25
08/28
Hu-Lieskovan, Siwen
BA3071-001, NCT05180799: A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

Recruiting
1/2
320
US, RoW
BA3071, Nivolumab, Pembrolizumab, Pemetrexed (Alimta)
BioAtla, Inc.
NSCLC, Melanoma
12/25
06/26
PRESERVE-001, NCT04140526: Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Recruiting
1/2
733
US, RoW
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody made by OncoC4, Inc., Pembrolizumab, Keytruda, MK3475, Docetaxel, Taxotere, Docefrez
OncoC4, Inc., National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
06/26
12/27
NCT05267626: Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Recruiting
1/2
159
US, RoW
AU-007, Aldesleukin, Avelumab
Aulos Bioscience, Inc.
Advanced Solid Tumor, Metastatic Cancer
08/25
09/25
BA3021-001, NCT03504488 / 2022-000137-17: CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Completed
1/2
132
Europe, US, RoW
CAB-ROR2-ADC, BA3021, PD-1 inhibitor
BioAtla, Inc., BioAtla Inc.
Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
12/24
12/24
KEYNOTE-C82, NCT04648202: FS120 Phase 1/1b Study in Patients With Advanced Malignancies

Active, not recruiting
1
82
Europe, US
FS120, Pembrolizumab (KEYTRUDA®)
invoX Pharma Limited, Merck Sharp & Dohme LLC
Advanced Cancer, Metastatic Cancer
03/26
03/26
CA101-001, NCT04423029 / 2021-000038-33: A Study of DF6002 Alone and in Combination With Nivolumab

Recruiting
1
438
Europe, US, RoW
DF6002, Nivolumab, Opdivo
Dragonfly Therapeutics
Solid Tumors
01/27
11/27
LYL845-101, NCT05573035: A Study to Investigate LYL845 in Adults With Solid Tumors

Active, not recruiting
1
108
US
LYL845
Lyell Immunopharma, Inc.
Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer
08/25
09/27

Download Options